Patient-Reported Symptom Experiences Following Participation in a Study of Telotristat Etiprate for Patients with Neuroendocrine Tumors and Diarrhea Not Adequately Controlled on Octreotide

#849

Introduction: Telotristat etiprate (LX1606), an oral tryptophan hydroxylase (TPH) inhibitor, was recently evaluated in a dose-escalation (DE) study in patients (pts) with carcinoid tumors and diarrhea not adequately controlled on octreotide.

Aim(s): The current study was designed to characterize the symptom experiences of those pts.

Materials and methods: Consenting pts participated in semi-structured, 1-on-1, qualitative interviews to record symptoms and the recollection of changes in symptoms experienced while participating in the DE study. After the interviews, pts completed the EORTC-QLQ-C30 and GI.NET-21 questionnaires.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Kulke M

Authors: Kulke M, O’Dorisio T, Yang Q, Jackson J, Jackson S,

Keywords: carcinoid, interview, symptom improvement,